Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network during the first and second pandemic waves.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 6511-6511
Author(s):  
Valentina Guarneri ◽  
Mario Caccese ◽  
Giuseppe Azzarello ◽  
Franco Bassan ◽  
Vanna Chiarion-Sileni ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Clinical Characteristics ◽  
Clinical Course ◽  
Lung Metastases ◽  
Cancer Type ◽  
Risk Of Death ◽  
Source Of Infection ◽  
All Cause Mortality ◽  
Ecog Ps ◽  
Hospital Contact

6511 Background: Since the beginning of the COVID-19 outbreak, the Veneto Oncology Network ROV licensed dedicated guidelines for cancer patients care during the pandemic, and developed a regional registry (ROVID) aimed at describing epidemiology and clinical course of SARS-CoV-2 infection in cancer patients. Preliminary data on 170 patients mainly diagnosed during the first pandemic wave have been published (Guarneri V, Eur J Cancer 2021). Here we report the data of additional 270 patients, comparing clinical data and outcomes between first (W1) and second (W2) pandemic waves. Methods: All patients with cancer diagnosis and documented SARS-CoV-2 infection are eligible. Data on diagnosis, comorbidities, anticancer treatments, details on SARS-CoV-infection including source of contagion, clinical presentation, hospitalization, treatments and fate of the infection are recorded. Results: 440 patients have been enrolled, 196 diagnosed during W1 (until September 2020) and 244 during W2. The most common cancer type was breast cancer (n = 116). Significant differences in clinical characteristics between W1 and W2 were the followings: ECOG PS 0 (34% vs 58%), presence of cardiac comorbidities (30% vs 13%), presence of any co-morbidities (81% vs 62%), smoking habits (23% vs 13%). Patients diagnosed in W1 were less likely on active anticancer therapy (54% vs 73%) at the time of SARS-CoV-2 infection. Distribution per stage, presence of lung metastases, disease setting (curative vs palliative), active treatment discontinuation due to infection were similar between W1 and W2. Patients diagnosed in W1 were more likely symptomatic for SARS-CoV-2 infection (80% vs 67%), and reported more frequently an in-hospital contact as potential source of infection (44% vs 9%). Significantly more patients diagnosed in W1 were hospitalized (76% vs 25%). All-cause mortality rates were 30.6% for patients diagnosed in W1 vs 12% for patients diagnosed in W2 (p < 0.001). However, deaths due to SARS-CoV-2 infection were more frequent in patients diagnosed in W2 (86% vs 54%, odds ratio 3.22; 95% CI 1.97-5.279). Conclusions: Differences in clinical characteristics between W1 and W2 reflect different pattern of virus circulation. The dramatic reduction of in-hospital contact as a source of infection reflects the efforts put in place to protect this vulnerable population from in-hospital exposure. The lower all-cause mortality rate observed in W2 is in line with the observed less frail population. However, the higher relative risk of death due to SARS-CoV-2 infection observed in W2 reinforces the need to adopt protective measures including vaccination in cancer patients, irrespectively of age, stage, and comorbidities.

Prognostic utility of differential contrast-enhancement patterns on late gadolinium enhancement cardiac MRI (LGE-CMR) in patients with cancer-associated cardiac masses

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A Chan ◽  
W Dinsfriend ◽  
J Kim ◽  
R Steingart ◽  
J.W Weinsaft
Keyword(s):  
Contrast Enhancement ◽  
Cancer Patients ◽  
Cancer Type ◽  
Tissue Properties ◽  
All Cause Mortality ◽  
Prognostic Utility ◽  
Cardiac Masses ◽  
Embolic Risk ◽  
Lge Cmr

Abstract Background LGE-CMR tissue characterization is widely used to identify cardiac masses (CMASS) in cancer patients – including neoplasm (NEO) and thrombus (THR). Prognostic utility of their differential LGE patterns is unknown. Purpose To determine incremental prognostic utility of LGE patterns in CMASS Methods The population comprised of cancer patients with CMASS on LGE-CMR, for which etiology was classified based on presence (NEO) or absence (THR) of enhancement, and controls matched for cancer type/stage. LGE-CMR tissue properties of NEO was classified based on extent of contrast enhancement – diffusely enhancing (DE), mixed (ME), and predominantly avascular (PA). Clinical follow up was performed for embolic events within 6 months of CMR and all-cause mortality. Results 330 cancer patients (55% M; 55±16yo) with an array of cancer diagnoses (19% sarcoma, 17% GI, 13% GU) were studied. Among CMASS+ pts (n=190), 66% had NEO and 34% had THR on LGE. All THR were non-enhancing. Among NEO, LGE pattern was variable (46% DE, 41% ME, 13% PA); ME lesions were larger than other groups (Fig. 1A). Quantitative tissue properties were consistent with qualitative groups, as evidenced by stepwise variation in signal intensity and CNR. Cumulative embolic events were 3-fold higher in CMASS+ than controls (All: 20% vs. 7%, p=0.001; PE: 13% vs. 5%, p=0.02; CVA/systemic embolism: 10% vs. 3%, p=0.01). Median time to event was 1.3 months [IQR 0.1–2.3] from CMR. Aggregate events were similar between NEO and THR, reflecting similar rates of PE and CVA (p=NS). Among CMASS pts with embolic events, 56% were on anticoagulation at time of event (59% NEO, 50% THR, p=0.61). Regarding CMASS morphology, emboli were 3-fold higher among intracavitary (IC) or highly mobile (HM) CMASS (IC: 25% vs 7%, p&lt;0.001; HM: 38% vs 12%, p=0.001). Regarding location, right sided CMASS were associated with a 3–5 fold increase in PE (IC: 19% vs 6%; HM: 35% vs 7%, both p&lt;0.001) and similar CVA events among left sided CMASS (IC: 17% vs. 6%, p=0.02; HM: 33% vs 6%, p=0.05). Embolic events were similar when partitioned based on quantitative LGE patterns between patients with and without embolic events. As for all-cause mortality, NEO on CMR conferred increased mortality than THR (HR 3.06 [CI=1.84–5.1], p&lt;0.001) and matched controls (HR 2.08 [CI=1.42–3.04], p&lt;0.001) during a median follow-up of 9.4 months [IQR 3.6–23.2]. Among NEO subgroups (Fig. 1B), survival was lower in patients with heterogeneous LGE patterns vs matched controls: the lowest survival in ME (p=0.002) suggests increased vascularity and tumor hypoxia/necrosis associated with aggressive tumors and hence larger lesions. Conclusions Among cancer patients, CMR-evidenced CMASS confers high short-term embolic risk, which are equivalently common between NEO and THR. Intra-cavitary location and increased mobility augment embolic risk irrespective of CMASS tissue properties whereas differential LGE patterns on CMR strongly impact prognosis. Funding Acknowledgement Type of funding source: None

scholarly journals Clinical characteristics and outcomes of adult patients admitted with COVID-19 in East London: a retrospective cohort analysis

2020 ◽  
Author(s):  
Daryl Oswald Cheng ◽  
Claire Jacqueline Calderwood ◽  
Erik Wilhelm Skyllberg ◽  
Adam Denis Jeremy Ainley
Keyword(s):  
Clinical Characteristics ◽  
Clinical Course ◽  
Cohort Analysis ◽  
Short Term ◽  
Asian Ethnicity ◽  
Persistent Symptoms ◽  
Risk Of Death ◽  
Increased Risk ◽  
Male Sex

AbstractBackgroundDescriptions of clinical characteristics of patients hospitalised with coronavirus disease 2019 (COVID-19), their clinical course and short-term in- and outpatient outcomes in deprived urban populations in the United Kingdom are still relatively sparse. We describe the epidemiology, clinical course, experience of non-invasive ventilation and intensive care, mortality and short-term sequalae of patients admitted to two large District General Hospitals across a large East London NHS Trust during the first wave of the pandemic.MethodsA retrospective analysis was carried out on a cohort of 1,946 patients with a clinical or laboratory diagnosis of COVID-19, including descriptive statistics and survival analysis. A more detailed analysis was undertaken of a subset of patients admitted across three Respiratory Units in the trust.ResultsIncreasing age, male sex and Asian ethnicity were associated with worse outcomes. Increasing severity of chest X-ray abnormalities trended with mortality. Radiological changes persisted in over 50% of cases at early follow up (6 weeks). Ongoing symptoms including hair loss, memory impairment, breathlessness, cough and fatigue were reported in 67% of survivors, with 42% of patients unable to return to work due to ongoing symptoms.ConclusionsUnderstanding the acute clinical features, course of illness and outcomes of COVID-19 will be vital in preparing for further peaks of the pandemic. Our initial follow up data suggest there are ongoing sequalae of COVID-19 including persistent symptoms and radiological abnormalities. Further data, including longer term follow up data, are necessary to improve our understanding of this novel pathogen and associated disease.Section 1: What is already known on this topicPrevious studies have reported that increasing age, male sex, Black and Asian ethnicity increased risk of death for patients admitted to hospital with coronavirus disease 2019 (COVID-19). There is little published literature regarding the follow up of patients with COVID-19.Section 2: What this study addsOur study is one of the first with follow up data for patients admitted to hospital with COVID-19. We show that radiological abnormality persisted at 6 weeks in over 50% of patients, as well as significantly increased breathlessness in patients without baseline dyspnoea. Our study confirms that increasing age, male sex and Asian ethnicity increased risk of death for patients, but also in an ethnically and socioeconomically diverse population in East London.

Anticoagulants for the treatment of venous thromboembolism in patients with cancer: An updated pairwise and network meta-analysis of randomized trials.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14692-e14692
Author(s):  
Shima Sidahmed ◽  
Ahmed Abdalla ◽  
Babikir Kheiri ◽  
Areeg Bala ◽  
Mohammed Salih ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Vitamin K ◽  
Major Bleeding ◽  
Metastatic Cancer ◽  
Meta Analysis ◽  
Number Needed To Treat ◽  
Cancer Type ◽  
Significant Difference ◽  
All Cause Mortality

e14692 Background: Cancer-associated venous thromboembolism (VTE) is common. Although low molecular weight heparin (LMWH) is the standard therapy in this setting, little is known with regard to non-vitamin K antagonist oral anticoagulants (NOACs). Therefore, we thought about evaluating the safety and efficacy of various anticoagulants in this vulnerable population. Methods: Electronic database search was conducted to identify randomized clinical trials (RCTs) that compared LMWH, NOACs, and/or vitamin-K-antagonists (VKA) in cancer patients. We performed frequentist direct and Bayesian network meta-analysis using random-effects model to calculate odds ratios (ORs), 95% confidence intervals (CIs), and 95% credible intervals (CrIs). The primary outcome was VTE (pulmonary embolism and deep-vein thrombosis) recurrence. Secondary outcomes were major bleeding and all-cause mortality. Results: We identified 13 RCTs with 6,595 total patients (mean age 62.4 ± 12.2; 50.4% female; 17.7% hematological malignancies; and 6 months median follow-up). The most common cancer type was colorectal and 48% of the population had metastatic cancer at baseline. NOACs were associated with significantly reduced VTE recurrence compared with VKA (OR = 0.58; 95% CI = 0.40-0.83; P < 0.01; number needed to treat [NNT] = 40) and LMWH (OR = 0.46; 95% CI = 0.25-0.85; P = 0.01; NNT = 20). LMHW was associated with significantly reduced VTE recurrence compared with VKA (OR = 0.52; 95% CI = 0.39-0.71; P < 0.01; NNT = 18). NOACs were associated with significantly reduced major bleeding compared with VKA (OR = 0.56; 95% CI = 0.35-0.91; P = 0.02; NNT = 64). There was no significant difference identified between the anticoagulant groups in regard to all-cause mortality. Conclusions: Among cancer patients with VTE, NOACs were associated with significantly reduced VTE recurrence compared to LMWH and VKA, and significantly reduced major bleeding compared with VKA. LMWH was associated with significantly reduced VTE recurrence compared with VKA.

Determinants of Outcome in Hospitalized Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: Results From National Surveillance in Canada, 2008-2012

2016 ◽  
Vol 37 (4) ◽  
pp. 390-397 ◽  
Author(s):  
Andrew E. Simor ◽  
Linda Pelude ◽  
George Golding ◽  
Rachel Fernandes ◽  
Elizabeth Bryce ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Soft Tissue ◽  
Bloodstream Infection ◽  
Antimicrobial Agents ◽  
Methicillin Resistant ◽  
Risk Of Death ◽  
Source Of Infection ◽  
All Cause Mortality ◽  
Staphylococcus Aureus Bloodstream Infection ◽  
Considerable Morbidity

BACKGROUNDBloodstream infection (BSI) due to methicillin-resistant Staphylococcus aureus (MRSA) is associated with considerable morbidity and mortality.OBJECTIVETo determine the incidence of MRSA BSI in Canadian hospitals and to identify variables associated with increased mortality.METHODSProspective surveillance for MRSA BSI conducted in 53 Canadian hospitals from January 1, 2008, through December 31, 2012. Thirty-day all-cause mortality was determined, and logistic regression analysis was used to identify variables associated with mortality.RESULTSA total of 1,753 patients with MRSA BSI were identified (incidence, 0.45 per 1,000 admissions). The most common sites presumed to be the source of infection were skin/soft tissue (26.6%) and an intravascular catheter (22.0%). The most common spa types causing MRSA BSI were t002 (USA100/800; 55%) and t008 (USA300; 29%). Thirty-day all-cause mortality was 23.8%. Mortality was associated with increasing age (odds ratio, 1.03 per year [95% CI, 1.02–1.04]), the presence of pleuropulmonary infection (2.3 [1.4–3.7]), transfer to an intensive care unit (3.2 [2.1–5.0]), and failure to receive appropriate antimicrobial therapy within 24 hours of MRSA identification (3.2 [2.1–5.0]); a skin/soft-tissue source of BSI was associated with decreased mortality (0.5 [0.3–0.9]). MRSA genotype and reduced susceptibility to vancomycin were not associated with risk of death.CONCLUSIONSThis study provides additional insight into the relative impact of various host and microbial factors associated with mortality in patients with MRSA BSI. The results emphasize the importance of ensuring timely receipt of appropriate antimicrobial agents to reduce the risk of an adverse outcome.Infect. Control Hosp. Epidemiol. 2016;37(4):390–397

scholarly journals Comparison of the Clinical Characteristics and Mortality of Adults Infected with Human Coronaviruses 229E and OC43

2019 ◽  
Author(s):  
Won-Il Choi ◽  
Choong Won Lee
Keyword(s):  
Clinical Characteristics ◽  
Respiratory Virus ◽  
University Teaching ◽  
Multivariate Logistic Regression ◽  
Risk Of Death ◽  
All Cause Mortality ◽  
Polymerase Chain ◽  
Respiratory Virus Infection ◽  
Human Coronaviruses ◽  
Hospital Inpatients

Abstract Background: There are few studies on the epidemiology and prognosis of coronavirus infections among patients seen in emergency departments and hospital inpatients. The purpose of the study was to compare clinical characteristics and mortality among adults infected with human coronaviruses (HCoV) 229E and OC43. Methods: We conducted a retrospective cohort study of adults (≥18 years) admitted to the emergency department and ward of a university teaching hospital for suspected viral infection from October 2012 to December 2017. Multiplex real-time polymerase chain reaction (PCR) was used to test for respiratory viruses. Multivariate logistic regression was used to compare mortality among patients with HCoV 229E and HCoV OC43 infections. The main outcome was 30-day all-cause mortality. Results: Of 8,071 patients tested, 1,689 were found to have a respiratory virus infection. Of these patients, 133 had an HCoV infection, including 12 mixed infections, 44 HCoV 229E infections, and 77 HCoV OC43 infection s. HCoV 229E infections peaked in January and February, while HCoV OC43 infections occurred throughout the year. Sixteen patients (13.2%) with HCoV infections required admission to the intensive care unit. The 30-day all-cause mortality was 22.7% among patients with HCoV 229E infection, and 11.6% among patients with HCoV OC43 infection . Patients infected with HCoV 229E infection had a higher risk of death than those with HCoV OC43 infection (adjusted odds ratio: 2.11, 95% confidence interval: 0.74-6.05). Conclusions: Infections with HCoVs 229E and OC43 appear to have different seasonal patterns, and HCoV 229E might be more virulent than HCoV OC43.

scholarly journals P0807THE IMPACT OF GLOMERULAR FILTRATION RATE IN HEART FAILURE PATIENTS WITH CARDIAC IMPLANTABLE DEVICES - MYTH OR FACT?

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Natacha Rodrigues ◽  
Afonso N Ferreira ◽  
Pedro António ◽  
Mafalda Carrington ◽  
João De Sousa ◽  
...  
Keyword(s):  
Glomerular Filtration Rate ◽  
Glomerular Filtration ◽  
Clinical Characteristics ◽  
Filtration Rate ◽  
Independent Predictor ◽  
Implantable Devices ◽  
Risk Of Death ◽  
All Cause Mortality ◽  
The Impact

Abstract Background and Aims Heart Failure (HF) and chronic kidney disease (CKD) are both epidemic, frequently simultaneous and sharing well knowned risk factors. Implantable devices can improve quality of life and reduce mortality in a selected population. Data derived from meta-analyses show both survival benefit in CKD patients receiving devices and increased risk of death in device patients with CKD. Little is Known about the impact of glomerular filtration rate (GFR) across the different stages of CKD in the vital prognoses of HF patients submitted to cardiac resynchronization therapy (CRT) or implantable cardiac defibrillator (ICD) implants. To evaluate the impact of CKD in all-cause mortality in HF patients who implanted a CRT or ICD. Method Prospective single-center study of patients who implanted CRT or ICD between 2015 and 2019. Clinical characteristics were evaluated at baseline and mortality was assessed using the national registry. CKD was evaluated according to the GFR by CKD-EPI equation according to the KDIGO guidelines. We performed univariate and multivariate analysis to compare clinical characteristics of patients who died and who survived using the Cox regression and Kaplan-Meier methods. For the predictor GFR levels, and according to the KDIGO classification, we assessed the best cut-off value for mortality using the area under the ROC curve (AUC) method. Results From 2015-2019, 974 devices were implanted, 414 ICDs and 560 CRTs (23.3% female, 67.6±12.1, follow-up duration 26.4±16.5 months). A total of 161 patients (16.5%) died during follow-up. GFR at the time of device implant was significantly lower in patients who died compared to those who survived (49.7 vs 67.3ml/min/1.73m2, p&lt;0.001). When evaluating predictors for all-cause mortality by multivariate analysis, GFR at the time of device implant was an independent predictor of mortality, even when adjusted for age, gender, arterial hypertension and diabetes (HR 1.12; 95% CI 1.04-1.16, p&lt;0.001). The best GFR cut-off value to predict mortality with a 69% sensitivity and 65% specificity was 75ml/min/1.73m2 (AUC 0.70). Patients with a GFR &lt; 75ml/min/1.73m2 at the time of implant have a 2.5-fold higher risk of death (HR 2.5; 95% CI 1.6-3.9, p&lt;0.001). Risk of death significantly increases along GFR decline, almost doubling each stage, with 2.7 for stage 3a (p=0.2), 5.5 for stage 3b, 9.5 for stage 4 and 14.7-fold higher risk of death for stage 5 (p&lt;0.001). Conclusion In our cohort of HF patients who underwent CRT or ICD implant, glomerular filtration rate was an independent predictor for all-cause mortality. Additionally, GFR&lt;75ml/min/1.73m2 at the time of device implant increased by 2.5-fold the risk of death, the risk doubles for each CKD stage increase, reaching a dramatic 14.7- fold higher risk of death for stage 5 patients. CKD should not postpone device implant, as its deterioration significantly increases the risk of death.

scholarly journals Thrombocytopenia Among Patients with Hematologic Malignancies and Solid Tumors: Risk and Prognosis

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3156-3156
Author(s):  
Kasper Adelborg ◽  
Katalin Veres ◽  
Erzsébet Horváth-Puhó ◽  
Mary Clouser ◽  
Hossam A Saad ◽  
...  
Keyword(s):  
Platelet Count ◽  
Cancer Patients ◽  
Solid Tumors ◽  
Clinical Outcomes ◽  
Cancer Diagnosis ◽  
Hematologic Malignancies ◽  
Severe Thrombocytopenia ◽  
Cancer Type ◽  
Risk Of Death ◽  
Study Inclusion

Abstract Introduction: Despite the large body of research in cancer and increasing numbers of cancer survivors, knowledge about the risks and prognoses related to thrombocytopenia in the clinical care setting is scarce. Such information is important to understanding the need and potential impact of platelet transfusion and emerging drug therapies for thrombocytopenia. In this study, we examined the risk of thrombocytopenia among patients with incident cancer. Further, we studied the extent to which thrombocytopenia was associated with adverse clinical outcomes. Methods: This population-based cohort study was conducted using data from the Danish Cancer Registry. All patients diagnosed with incident hematologic malignancies and solid tumors (age of ≥18 years) during 2015─2018 were identified. Data were linked with routine laboratory test results from the primary care and hospital settings, as recorded in the Danish Register of Laboratory Results for Research. Based on platelet count levels (x 10 9/L), thrombocytopenia was categorized as grade 0 (any count)&lt;150; grade 1:&lt;100; grade 2:&lt;75; grade 3:&lt;50; and grade 4: &lt;25. We tabulated the prevalence of thrombocytopenia at study inclusion and calculated the cumulative incidence proportion (risk) of thrombocytopenia, accounting for the competing risk of death. Each patient with thrombocytopenia was matched up to 5 cancer patients without thrombocytopenia by age, sex, cancer type, cancer stage, and time from cancer diagnosis and index date. Cox proportional hazards regression analysis was used to compute hazard ratios (HRs) with 95% confidence intervals (CIs) of adverse clinical outcomes, including any bleeding leading to hospitalization, site-specific bleeding leading to hospitalization, transfusion (red blood cell, platelet, or fresh frozen plasma), and death. HRs were adjusted for Charlson Comorbidity Index scores and matching factors by design. Results: The analytic cohort comprised 11,785 patients with hematologic malignancies and 57,600 patients with solid tumors (median age=70 years). Any thrombocytopenia was observed during the 6 months preceding study inclusion among 18% of patients with hematologic malignancies (grades 1-2: 6% and grades 3-4: 5%) and 4% of patients with solid tumors (grades 1-2: 1% and grades 3-4: 0%). The 1-year and 4-year risks of new-onset thrombocytopenia were 30% and 40% for hematologic malignancies and 21% and 28% for solid tumors, respectively (Figure 1). Among patients who initiated chemotherapy following their cancer diagnosis (n=33,165), the 1-year and 4-year risks of thrombocytopenia were 50% and 62% for hematologic malignancies and 39% and 49% for solid tumors, respectively (Figure 2). Patients with grade 4 thrombocytopenia had higher rates of any bleeding leading to hospitalization than patients without thrombocytopenia [hematologic malignancies: HR=2.31 (95% CI: 1.43-3.73) and solid tumors: HR=4.52 (95% CI: 2.00-10.24)], while grades 1-3 thrombocytopenia did not confer a significantly increased rate of hospitalization for bleeding (Table 1). All grades of thrombocytopenia were associated with an increased rate of transfusion [overall for hematologic malignancies: HR=2.06 (95% CI: 1.91-2.23), and overall for solid tumors: HR=2.13 (95% CI: 1.83-2.48)] and with death [overall for hematologic malignancies: HR=2.01 (95% CI: 1.84-2.20), and overall for solid tumors: HR=1.44 (95% CI: 1.39-1.49)]. These associations increased in magnitude with decreasing platelet count levels. Conclusions: The risk of thrombocytopenia was substantial following a diagnosis of incident hematologic malignancy and solid tumors, with higher risks among patients who initiated chemotherapy. While only severe thrombocytopenia was a predictor of any hospitalization for bleeding, all grades of thrombocytopenia were associated with increased rates of transfusion and death. Our findings support the need for regular assessment of platelet count levels to identify cancer patients at risk of serious clinical outcomes. Figure 1 Figure 1. Disclosures Clouser: Amgen: Current Employment, Other: This work is related to Chemotherapy Induced Thrombocytopenia as a disease state, in this essence it is not directly related to an Amgen product; CIT is an area of scientific interest to Amgen with Romiplostim under development for this potential indicati. Saad: Amgen: Current Employment, Current equity holder in publicly-traded company.

Incidental Venous Thromboembolism in Kidney Cancer Patients: A Retrospective Case-Control Study

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 5134-5134
Author(s):  
Daniel W Yokom ◽  
Ryma Ihaddadene ◽  
Gregoire Le Gal ◽  
Marc Carrier
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Kidney Cancer ◽  
Cancer Diagnosis ◽  
Case Control ◽  
Hazard Ratio ◽  
Cancer Type ◽  
Control Analysis ◽  
Retrospective Case ◽  
Risk Of Death

Abstract Abstract 5134 Introduction: The incidence of venous thromboembolism (VTE) in kidney cancer patients has been reported at 1. 2–3. 2% with an estimated hazard ratio for death of 1. 3–3. 2. Computed Tomography (CT) scans are used frequently to stage cancer, and as the resolution of the scans increases more incidentally discovered asymptomatic VTE are being diagnosed. Currently, it is unclear if incidentally found VTE have the same effect on survival as symptomatic VTE in kidney cancer patients. Methods: We undertook a retrospective case-control analysis of all kidney cancer patients treated at our institution between January 1, 2005 and July 1, 2012. Cases with VTE were matched in a ratio of 1:2 to controls by gender, age and stage at cancer diagnosis. All charts were reviewed for comorbidities at cancer diagnosis, cancer type, stage, and treatment plan. We reviewed imaging studies to identify the location of the VTE and whether it was unsuspected – which was defined as a VTE found on a CT which was indicated for cancer staging. Results: From a cohort of 1166 primary kidney cancer patients we identified 68 (5. 8%) patients who developed a VTE. There were 30 cases of pulmonary embolism (PE), 24 lower extremity deep vein thrombosis (DVT), 5 DVT of the upper extremity and neck and 9 intra-abdominal VTE. Of these, 35% were discovered incidentally and 65% were symptomatic. Compared to matched controls, all patients with VTE did not have worsened survival (hazard ratio [HR] = 0. 87; 95% CI: 0. 54–1. 42). As demonstrated in Figure 1, symptomatic and incidentally discovered VTE were at no increased risk of death compared to controls (HR = 0. 72; 95% CI: 0. 40 – 1. 31 and HR = 1. 12; 95% CI: 0. 61 – 2. 27 respectively). Also, when looking specifically at symptomatic and incidentally discovered pulmonary embolisms, no difference in survival was detected (HR = 1. 44; 95% CI: 0. 68 – 3. 06 and HR = 0. 78; 95% CI: 0. 31 – 1. 97 respectively). Conclusions: In this analysis of kidney cancer patients we found a high rate of VTE (5. 8%) of which 35% were found incidentally on CT staging. The results from this study show that kidney cancer patients with VTE do not have worse survival outcomes than those without VTE. Moreover, the difference in survival between patients with any symptomatic VTE or PE does not differ from incidentally found VTE or PE. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Association between use of urgent suspected cancer referral and mortality and stage at diagnosis: a 5-year national cohort study

2020 ◽  
Vol 70 (695) ◽  
pp. e389-e398 ◽  
Author(s):  
Thomas Round ◽  
Carolynn Gildea ◽  
Mark Ashworth ◽  
Henrik Møller
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Late Stage ◽  
Significant Proportion ◽  
Cancer Type ◽  
Stage At Diagnosis ◽  
Risk Of Death ◽  
Urgent Referral ◽  
National Cohort

BackgroundThere is considerable variation between GP practices in England in their use of urgent referral pathways for suspected cancer.AimTo determine the association between practice use of urgent referral and cancer stage at diagnosis and cancer patient mortality, for all cancers and the most common types of cancer (colorectal, lung, breast, and prostate).Design and settingNational cohort study of 1.4 million patients diagnosed with cancer in England between 2011 and 2015.MethodThe cohort was stratified according to quintiles of urgent referral metrics. Cox proportional hazards regression was used to quantify risk of death, and logistic regression to calculate odds of late-stage (III/IV) versus early-stage (I/II) cancers in relation to referral quintiles and cancer type.ResultsCancer patients from the highest referring practices had a lower hazard of death (hazard ratio [HR] = 0.96; 95% confidence interval [CI] = 0.95 to 0.97), with similar patterns for individual cancers: colorectal (HR = 0.95; CI = 0.93 to 0.97); lung (HR = 0.95; CI = 0.94 to 0.97); breast (HR = 0.96; CI = 0.93 to 0.99); and prostate (HR = 0.88; CI = 0.85 to 0.91). Similarly, for cancer patients from these practices, there were lower odds of late-stage diagnosis for individual cancer types, except for colorectal cancer.ConclusionHigher practice use of referrals for suspected cancer is associated with lower mortality for the four most common types of cancer. A significant proportion of the observed mortality reduction is likely due to earlier stage at diagnosis, except for colorectal cancer. This adds to evidence supporting the lowering of referral thresholds and consequent increased use of urgent referral for suspected cancer.

scholarly journals Prevalence and in-hospital outcomes of patients with malignancies undergoing de novo cardiac electronic device implantation in the USA

EP Europace ◽  
2020 ◽  
Vol 22 (7) ◽  
pp. 1083-1096
Author(s):  
Mohamed O Mohamed ◽  
Ana Barac ◽  
Tahmeed Contractor ◽  
Helme Silvet ◽  
Ruben Casado Arroyo ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Major Bleeding ◽  
De Novo ◽  
Electronic Device ◽  
Negative Impact ◽  
Major Adverse Cardiovascular Events ◽  
Cardiac Complications ◽  
Cancer Type ◽  
Hospital Outcomes ◽  
All Cause Mortality

Abstract Aims To study the outcomes of cancer patients undergoing cardiac implantable electronic device (CIED) implantation. Methods and results De novo CIED implantations (2004–15; n = 2 670 590) from the National Inpatient Sample were analysed for characteristics and in-hospital outcomes, stratified by presence of cancer (no cancer, historical and current cancers) and further by current cancer type (haematological, lung, breast, colon, and prostate). Current and historical cancer prevalence has increased from 3.3% to 7.8%, and 5.8% to 7.8%, respectively, between 2004 and 2015. Current cancer was associated with increased adjusted odds ratio (OR) of major adverse cardiovascular events (MACE) [composite of all-cause mortality, thoracic and cardiac complications, and device-related infection; OR 1.26, 95% confidence interval (CI) 1.23–1.30], all-cause mortality (OR 1.43, 95% CI 1.35–1.50), major bleeding (OR 1.38, 95% CI 1.32–1.44), and thoracic complications (OR 1.39, 95% CI 1.35–1.43). Differences in outcomes were observed according to cancer type, with significantly worse MACE, mortality and thoracic complications with lung and haematological malignancies, and increased major bleeding in colon and prostate malignancies. The risk of complications was also different according to CIED subtype. Conclusion The prevalence of cancer patients amongst those undergoing CIED implantation has significantly increased over 12 years. Overall, current cancers are associated with increased mortality and worse outcomes, especially in patients with lung, haematological, and colon malignancies whereas there was no evidence that historical cancer had a negative impact on outcomes.

Sign in / Sign up

Export Citation Format

Share Document